CLVS News and Press, Clovis Oncology Inc. From 08/08/22

Shares of the cancer drugmaker Clovis Oncology (NASDAQ: CLVS) are under pressure yet again today. As of 12:47 p.m. ET on Monday, the company's stock price was down by a noteworthy 12.8% on relatively modest volume. After this latest dip, Clovis' stock is down by over 46% for the yea...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Clovis Oncology (NASDAQ: CLVS ) stock is down more than 10% today after posting its second-quarter financial results . The biopharmaceutical company missed on revenue and profits, leading the way for today’s s...

Clovis Oncology, Inc. (CLVS) Q2 2022 Earnings Conference Call August 08, 2022, 08:30 ET Company Participants Anna Sussman - VP, IR Patrick Mahaffy - Co-Founder, CEO, President & Executive Director Lindsey Rolfe - EVP, Clinical Development & Pharmacovigila...

The shares of commercial stage biotech Clovis Oncology, Inc. ( NASDAQ: CLVS ) fell ~15% in the pre-market Monday after the company highlighted the need to raise additional capital following a sales decline for its anti-cancer medication Rubraca in 2Q 2022. The company re...

Clovis Oncology press release ( NASDAQ: CLVS ): Q2 GAAP EPS of -$0.50 misses by $0.07 . Revenue of $32.14M (-12.7% Y/Y) misses by $4.94M . Clovis had $94.6M in cash and cash equivalents as of June 30, 2022. Cash used in operating activities down $23.4M or 4...

First presentation of initial LuMIERE Phase 1 clinical data for FAP-2286 targeted radiotherapy candidate at SNMMI demonstrated a manageable safety profile with preliminary evidence of activity Confirmed partial response in one patient in the lowest (3.7 GBq) dose cohort ...

Clovis Oncology ( NASDAQ: CLVS ) is scheduled to announce Q2 earnings results on Monday, August 8th, before market open. The consensus EPS Estimate is -$0.43 (+29.5% Y/Y) and the consensus Revenue Estimate is $37.08M (+0.7% Y/Y). Over the last 3 months, EPS estimates h...

ANIP , APRN , ASRT , BNTX , CLVS , D , DCTH , DTIL , ELAN , ENR , FREY , GOLD , HE , HEP , ITUB , KNDI , KOS , LINC , OTCPK:LKNCY , OSG , PDSB , PLTR , PRTY , RDWR , RETA , SOHU , TGN...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips In recent weeks, the stock market has stabilized after June’s sell-off, but it may take time before bullishness makes a comeback. Plenty of uncertainty remains, including further interest rate hikes , continued high...

The European Medicines Agency (EMA) announced on Friday Rubraca (rucaparib camsylate), a cancer medication marketed by the U.S. biotech Clovis Oncology ( NASDAQ: CLVS ) should no longer be used as a third line treatment for certain cancers due to concerns over safety/quality. ...